checkAd
    Startseite > Aktien > BioCardia > Nachrichten
    BioCardia Aktie
    0,3728
     
    USD
    +1,30 %
    +0,0048 USD
    Letzter Kurs 27.04.24 NYSE
    0,3690
     
    USD
    100 STK
    Geldkurs 26.04.24
    0,3900
     
    USD
    100 STK
    Briefkurs 26.04.24
    ISIN: US09060U5074 · WKN: A2PLXH · SYM: BCDA · USA

    Neueste Nachrichten

    BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort
    25.04.24 · globenewswire · BioCardia
    BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results
    27.03.24 · globenewswire · BioCardia
    BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024
    20.03.24 · globenewswire · BioCardia
    BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
    13.03.24 · globenewswire · BioCardia
    BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study
    12.03.24 · globenewswire · BioCardia
    BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure
    04.03.24 · globenewswire · BioCardia
    BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA
    08.02.24 · globenewswire · BioCardia
    BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference
    31.01.24 · globenewswire · BioCardia
    BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders
    03.01.24 · globenewswire · BioCardia
    BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction
    19.12.23 · globenewswire · BioCardia
    BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes
    18.12.23 · globenewswire · BioCardia
    BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval
    29.11.23 · globenewswire · BioCardia